ES2088959T3 - 11-beta-aril-4-estreno, procedimiento para su preparacion y aplicacion como medicamento. - Google Patents

11-beta-aril-4-estreno, procedimiento para su preparacion y aplicacion como medicamento.

Info

Publication number
ES2088959T3
ES2088959T3 ES90250142T ES90250142T ES2088959T3 ES 2088959 T3 ES2088959 T3 ES 2088959T3 ES 90250142 T ES90250142 T ES 90250142T ES 90250142 T ES90250142 T ES 90250142T ES 2088959 T3 ES2088959 T3 ES 2088959T3
Authority
ES
Spain
Prior art keywords
preparation
premiere
aril
beta
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90250142T
Other languages
English (en)
Inventor
Arwed Dr Cleve
Cornelius Dr Scheidges
Gunter Dr Neef
Eckhard Dr Ottow
Walter Dr Elger
Sybille Dr Beier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2088959T3 publication Critical patent/ES2088959T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0085—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0092—Alkenyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Led Device Packages (AREA)
  • Magnetic Heads (AREA)
  • Pressure Sensors (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE DESCRIBEN COMPUESTOS CON FORMULA GENERAL (I) (FORMULA) EN LA QUE X, R1, R2, R3 Y R4 TIENEN EL SIGNIFICADO EXPUESTO EN LAS REIVINDICACIONES. SE DESCRIBEN SU FABRICACION Y LOS PREPARADOS FARMACEUTICOS, QUE LOS CONTIENEN. LOS COMPUESTOS POSEEN EFECTOS ANTIGLUCOCORTICOIDES.
ES90250142T 1989-06-23 1990-06-01 11-beta-aril-4-estreno, procedimiento para su preparacion y aplicacion como medicamento. Expired - Lifetime ES2088959T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3921059A DE3921059A1 (de) 1989-06-23 1989-06-23 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
ES2088959T3 true ES2088959T3 (es) 1996-10-01

Family

ID=6383695

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90250142T Expired - Lifetime ES2088959T3 (es) 1989-06-23 1990-06-01 11-beta-aril-4-estreno, procedimiento para su preparacion y aplicacion como medicamento.

Country Status (19)

Country Link
US (2) US5843933A (es)
EP (1) EP0404283B1 (es)
JP (1) JP2911553B2 (es)
CN (2) CN1048499C (es)
AT (1) ATE137762T1 (es)
AU (1) AU640664B2 (es)
CA (1) CA2019404C (es)
DD (1) DD295639A5 (es)
DE (2) DE3921059A1 (es)
DK (1) DK0404283T3 (es)
ES (1) ES2088959T3 (es)
FI (1) FI111844B (es)
GR (1) GR3020098T3 (es)
HU (1) HU209949B (es)
IE (1) IE74191B1 (es)
IL (1) IL94819A (es)
NO (1) NO178768C (es)
PT (1) PT94462A (es)
ZA (1) ZA904893B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
EP0460753A3 (en) * 1990-06-07 1992-04-15 Mogen International N.V. New antifungal preparations, process for making such preparations, process for obtaining plants with decreased susceptibility to fungi
DE4042007A1 (de) * 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
DE4434488A1 (de) 1994-09-14 1996-03-21 Schering Ag Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
ZA9510926B (en) 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
DE19610667C2 (de) * 1996-03-08 1998-04-09 Schering Ag (Z)-11ß-[4-(Dimethylamino)phenyl]17ß-hydroxy-17alpha-(3-hydroxy-1-propenyl)estr-4-en-3-on als kristallines Ansolvat
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US6090798A (en) * 1997-12-19 2000-07-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with glucocorticoid antagonists
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
KR100348888B1 (en) * 2001-12-11 2002-08-14 Chang Eun Jung Method for relieving violence and spare diet of estrous deer and method for promoting growth of antlers thereof
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
WO2008039482A2 (en) * 2006-09-26 2008-04-03 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
MY150763A (en) 2006-10-24 2014-02-28 Repros Therapeutics Inc Compositions and methods for suppressing endometrial proliferation
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
HUP0900487A2 (hu) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására
MX2012010327A (es) 2010-03-22 2012-11-16 Repros Therapeutics Inc Composiciones y metodos para la administracion no toxica de antiprogestinas.
WO2017112909A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP6906525B2 (ja) 2015-12-23 2021-07-21 オリック ファーマシューティカルズ，インク． グルココルチコイド受容体の阻害剤
PT3523315T (pt) * 2016-10-07 2021-04-29 Oric Pharmaceuticals Inc Inibidor de recetor de glucocorticoide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US4978657A (en) * 1981-01-09 1990-12-18 Roussel Uclaf Novel 11β-substituted-19-nor-steroids
FR2528434B1 (fr) * 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
DE3590389T1 (de) * 1984-08-02 1986-08-28 Schering Corp., Kenilworth, N.J. Pharmazeutische Zusammensetzung für eine Kombinationstherapie hormon-abhängiger Cancer
DE3506785A1 (de) * 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3761308D1 (de) * 1986-07-23 1990-02-08 Akzo Nv 18-phenylestrane-derivate.
US4774236A (en) * 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US4861763A (en) * 1986-09-17 1989-08-29 Research Triangle Institute 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
DE3702383A1 (de) * 1987-01-23 1988-08-04 Schering Ag 11ss-alkinylestrene und -estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2610933B1 (fr) * 1987-02-18 1989-06-09 Roussel Uclaf Nouveaux 19-nor steroides substitues en position 7, leur preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2620707B1 (fr) * 1987-09-18 1989-12-08 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel

Also Published As

Publication number Publication date
CN1061052C (zh) 2001-01-24
NO902800L (no) 1990-12-27
CN1048219A (zh) 1991-01-02
IL94819A (en) 1995-03-30
HU903961D0 (en) 1990-11-28
ZA904893B (en) 1991-04-24
CA2019404A1 (en) 1990-12-23
DD295639A5 (de) 1991-11-07
PT94462A (pt) 1991-02-08
DE59010312D1 (de) 1996-06-13
IE74191B1 (en) 1997-07-16
FI903153A0 (fi) 1990-06-21
HU209949B (en) 1994-12-28
US5728689A (en) 1998-03-17
NO178768B (no) 1996-02-19
IE902280L (en) 1990-12-23
AU640664B2 (en) 1993-09-02
CN1048499C (zh) 2000-01-19
IL94819A0 (en) 1991-04-15
EP0404283B1 (de) 1996-05-08
EP0404283A2 (de) 1990-12-27
EP0404283A3 (de) 1991-07-31
GR3020098T3 (en) 1996-08-31
FI111844B (fi) 2003-09-30
US5843933A (en) 1998-12-01
JP2911553B2 (ja) 1999-06-23
DK0404283T3 (da) 1996-09-09
CA2019404C (en) 2003-09-16
NO178768C (no) 1996-05-29
NO902800D0 (no) 1990-06-22
AU5778090A (en) 1991-01-03
IE902280A1 (en) 1991-01-16
ATE137762T1 (de) 1996-05-15
DE3921059A1 (de) 1991-01-10
JPH03128323A (ja) 1991-05-31
HUT54705A (en) 1991-03-28
CN1133296A (zh) 1996-10-16

Similar Documents

Publication Publication Date Title
NO902800D0 (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
DE3382641D1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
BR9405040A (pt) Compostos propinil biaromáticos, produto medicinal, composições farmacêuticas e cosméticas
ES2102475T3 (es) Nuevas alquil-amidas heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
NO890259D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider.
ES2145818T3 (es) Utilizacion de la (s)-(-)-alfa-etil-2-oxo-1-pirrolidin-acetamida para la preparacion de medicamentos destinados al tratamiento de la ansiedad.
ATE157871T1 (de) Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind
DK0406745T3 (da) Antibiotiske GE 2270 faktorer A1, A2, A3 og H
ATE137237T1 (de) R-(-)-1-(5-hydroxyhexyl)-3-methyl-7- propylxanthin, verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittel
ATE27157T1 (de) Cycloalkylderivate von benzisoselenazolonen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DE3261625D1 (en) Tricyclic thiazolyl oxamic acids and derivatives, process for their production, and therapeutic agents containing them
GR3018938T3 (en) 6-Oxopyridazine derivatives, process for their preparation and medicaments containing these compounds
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
IT1223395B (it) Composti ad attivita' cardiovascolare
DE59003446D1 (de) 13-Brom und 13, 14-Dibrom-Ergoline, ihre Herstellung und Verwendung in Arzneimitteln.
JPS6447759A (en) Leukotriene antagonists and manufacture
FI950575A7 (fi) 3- ja 5-substituoidut 1,2,3,4-oksatriatsoli-5-imiiniyhdisteet, niiden valmistusmenetelmä, mainittuja yhdisteitä sisältävä farmaseuttinen valmiste ja mainittujen yhdisteiden käyttö lääkkeiden valmistukseen
NO163283C (no) Analogifremgangsm te til fremstilling av terapeutisk aktive n-bicykloheptyl og n-bicykloheptenylimidazoler.
IT1166217B (it) Composizione farmaceutica per la terapia delle sterilita' maschile
ATE53384T1 (de) 3-mercapto-2-oxo-1-pyrrolidinessigsaeurederivate verfahren zur herstellung und pharmazeutische zusammensetzungen die sie enthalten.
AU6725387A (en) Drugs for the treatment and cure of all infectious diseases caused by pathogenic virulent micro-organisms
IT1158705B (it) N-(2-amino-cicloalifatico)aril-acilamidi ad attivita' terapeutica,loro preparazione e composizioni farmaceutiche contenenti tali composti

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 404283

Country of ref document: ES

FG2A Definitive protection

Ref document number: 404283

Country of ref document: ES